Figure 6.

Twenty-eight-day mortality in all randomly assigned patients in ADDRESS (a) and in PROWESS (b) with an APACHE II score of less than 25, with no patients removed from the analysis, and also with the first through fourth patients enrolled at each site removed. Note: 0 represents the results for the entire population, and 1 through 4 correspond to the analysis with the first through fourth patients from each site removed. ADDRESS, ADministration of DRotrecogin alfa (activated) in Early Stage Severe Sepsis; APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); PBO, placebo; PROWESS, Protein C Worldwide Evaluation in Severe Sepsis.